Skip to main content

Merck & Co., Inc. Pifeltro revenue

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026 · Market value $361.6B

Pifeltro revenue at Merck & Co., Inc. came to $43.0M for the quarter to 31 Dec 2025, up 7.5% from a year earlier.

As Merck & Co., Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 24 Feb 2026.

By quarter

$34.0MMar 2023$38.0MJun 2023$37.0MSep 2023$33.0MDec 2023$42.0MMar 2024$39.0MJun 2024$42.0MSep 2024$40.0MDec 2024$45.0MMar 2025$41.0MJun 2025$43.0MSep 2025$43.0MDec 2025
Merck & Co., Inc. Pifeltro revenue, every reported period
Period endingPifeltro revenueChange on a yearFiled
31 Dec 2025$43.0Mup 7.5%24 Feb 2026
30 Sep 2025$43.0Mup 2.4%5 Nov 2025
30 Jun 2025$41.0Mup 5.1%5 Aug 2025
31 Mar 2025$45.0Mup 7.1%2 May 2025
31 Dec 2024$40.0Mup 21.2%25 Feb 2025
30 Sep 2024$42.0Mup 13.5%6 Nov 2024
30 Jun 2024$39.0Mup 2.6%5 Aug 2024
31 Mar 2024$42.0Mup 23.5%3 May 2024
31 Dec 2023$33.0M—26 Feb 2024
30 Sep 2023$37.0M—3 Nov 2023
30 Jun 2023$38.0M—7 Aug 2023
31 Mar 2023$34.0M—5 May 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Merck & Co., Inc.: Keytruda revenue · Gardasil/Gardasil 9 revenue · Livestock revenue · Keytruda Qlex revenue · ProQuad/M-M-R II/Varivax revenue · Winrevair revenue · Companion Animal revenue · Lynparza alliance revenue · Prevymis revenue · Welireg revenue · Lenvima alliance revenue · Capvaxive revenue · RotaTeq revenue · Vaxneuvance revenue · Janumet revenue · Januvia revenue · Ohtuvayre revenue · Reblozyl alliance revenue · Bridion revenue · Adempas/Verquvo alliance revenue · Zerbaxa revenue · Adempas revenue · Delstrigo revenue · Isentress/Isentress HD revenue · financial statements

Every KPI and segment of MRK, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.